Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. develops and commercializes cell and gene therapies for serious diseases. Its updates center on ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa, including qualified treatment center activations, commercial launch activity, manufacturing and patient-treatment progress.
Company news also covers financial results, corporate progress, employee inducement equity awards under Nasdaq rules, board and committee changes, and development work involving AAV-based gene therapies and next-generation AAV capsids for ophthalmic and other serious diseases.
Abeona Therapeutics (Nasdaq: ABEO) will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. Results will be released in a press release before the call, with live access via phone and webcast, plus a 30-day archived replay on the company’s investor website.
Abeona Therapeutics (Nasdaq: ABEO) announced that the Centers for Medicare & Medicaid Services has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule. NTAP provides supplemental reimbursement above standard hospital payments for technologies that, according to CMS criteria, demonstrate substantial clinical improvement over existing alternatives.
ZEVASKYN is described as the first and only autologous cell sheet-based gene therapy to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). According to Abeona Therapeutics, ZEVASKYN has shown clinically meaningful wound healing and pain reduction after a single surgical application, and the company highlights NTAP as supporting Medicare patient access, treatment center economics, and reimbursement alongside its permanent J-code.
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees as material inducements to employment under Nasdaq Listing Rule 5635(c)(4). On July 31, 2026, Abeona’s Compensation Committee approved an aggregate of up to 10,800 restricted common shares, vesting in three equal annual installments over three years, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced that Cincinnati Children’s has been activated as the seventh Qualified Treatment Center (QTC) for administering ZEVASKYN (prademagene zamikeracel), an autologous gene-modified cellular sheet therapy for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
Cincinnati Children’s, described as one of the largest epidermolysis bullosa centers in the US, can now offer ZEVASKYN to adult and pediatric RDEB patients. Abeona highlighted its Abeona Assist program, which provides personalized support for insurance, financial assistance, and travel logistics. The release also reiterates ZEVASKYN’s mechanism, indication, clinically meaningful wound healing and pain reduction after a single surgical application, and key safety information, including risks of allergic reactions, potential cancer risk, infection transmission, and common side effects such as procedural pain and itching.
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
On June 30, 2026, five hires received restricted stock awards totaling up to 9,000 shares, vesting in three equal annual installments over three years, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the Compensation Committee approved restricted stock awards covering up to 13,800 shares, vesting in three equal annual installments over three years, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced participation in two investor conferences in June 2026.
Management will join a fireside chat at the 2026 Jefferies Global Healthcare Conference at 3:10 PM ET on Thursday, June 4, 2026, and hold investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026. A live webcast and replay of the Jefferies fireside chat will be available in the Investors "Events" section of Abeona's website.
Abeona Therapeutics (Nasdaq: ABEO) reported Q1 2026 net product revenue of $8.7 million, up from $2.4 million in Q4 2025, driven by ZEVASKYN.
Three patients were treated in Q1, the QTC network expanded to six sites, coverage policies now span 95% of commercially insured U.S. lives, and cash totaled $168.3 million.
Abeona Therapeutics (Nasdaq: ABEO) has activated Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for administering ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets to patients with recessive dystrophic epidermolysis bullosa (RDEB).
The designation expands access on the U.S. East Coast and is supported by Abeona Assist, a patient support program offering insurance, financial, travel, and logistical assistance.
Abeona Therapeutics (Nasdaq: ABEO) will report first-quarter 2026 financial results and host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET. The call is available by phone and via a live webcast, with an archived replay accessible on the company investor site for 30 days.
Dial-in numbers and an entry code are provided for live participation; a listen-only webcast and replay link are on the Abeona investor events page.